GLP-1
BioIVT will help to generate drug discovery target validation data and characterize novel therapeutics
Novo Nordisk’s oral-semaglutide for type 2 diabetes snagged approval from the U.S. Food and Drug Administration late Friday, marking it as the first such treatment to be approved in pill form.
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories.
Primary results showed significantly greater reduction in blood sugar levels over 26 weeks after switching to Soliqua® / Suliqua® 1 vs staying on daily or weekly GLP-1 receptor agonist
Adocia announced that it will deliver an oral presentation covering its ADO09 product at the 55th Annual Meeting of the European Association for the Study of Diabetes, being held September 16-20, 2019 in Barcelona, Spain.
Polyphor AG focused on the discovery and development of immuno-oncology compounds and a new class of antibiotics, publishes today its financial results for the first half of 2019 and announces a realignment of the strategy.
Recce Pharmaceuticals Ltd announced advances in scaled manufacture and drug quality following positive Food and Drug Administration feedback to its Chemistry, Manufacturing, and Controls data pack.
In the BioSpace poll, 55.17% of respondents said, Yes, companies should be allowed to sue competitors to prevent generic versions of their drugs, and 41.38% said no. A much smaller group, 3.45%, said they were unsure.
Total GIP NL-ELISA for specific determination of glucose-dependent insulinotropic peptide in human samples
Oncoceutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for ONC206, allowing the first-in-human trial of the compound. ONC206 is the first of the family of drug candidates, which we call “imipridones”, that possess the same core chemical structure as ONC201.
PRESS RELEASES